In this featured collection, we put a spotlight on medication assisted treatment (MAT) for opioid use disorder (OUD). Research has proven that MAT is an evidence-based strategy for treating individuals with OUD; individuals who use MAT as part of their treatment and recovery plan are more likely to be retained in treatment and to have fewer adverse events such as opioid overdose and opioid overdose mortality.
The Yale School of Medicine’s website contains comprehensive resources for providers interested in setting up a program to initiate buprenorphine treatment for individuals with opioid use disorder (OUD) seen in the emergency department (ED).
This program evaluation looks at California’s implementation of a hub-and-spoke treatment system for opioid use disorder (OUD) during the program’s first year (August 2017 to July 2018).
This 2 minute video accompanies the National Academies of Science, Engineering and Medicine’s report Medications for Opioid Use Disorder Save Lives.
This resource captures Oregon Health & Science University’s practice recommendations for the management of pain in patients on buprenorphine undergoing surgery and pregnant women during labor, delivery, and the post-partum period.
A brief overview of the emergency department (ED) based induction to buprenorphine program initiated at Yale New Haven Hospital. This report describes a randomized controlled trial that provided patients with opioid use disorder seen in the emergency room with either a substance use disorder screening and referral to treatment, a screening and brief intervention with facilitated referral to treatment, or induction to buprenorphine medicated assisted treatment and a referral to follow up treatment. Those patients offered buprenorphine were significantly more likely to be engaged in treatment 30 days later than the other patients. This model has subsequently been adopted in EDs across the country. This report is part of the Addiction Policy Forum’s Spotlight series which highlights innovative programs to address the opioid crisis.
In 2017 the Camden Coalition of Healthcare Providers began a pilot in partnership with local addiction treatment providers and UnitedHealthCare to see if removing prior authorization requirements for buprenorphine would reduce barriers to treatment and improve patient and system outcomes.
This 2018 evaluation of a pilot program to develop integrated medication assisted treatment (MAT) programs at community health centers (CHCs) describes the lessons learned by 10 CHCs as they implemented new MAT programs at their clinics in California.
This 2019 review from Oregon’s Drug Use Research & Management Program examined whether removing Medicaid prior authorization requirements for medication assisted treatment for individuals with opioid use
This 2018 publication from the National Sheriff’s Association and the National Commission on Correctional Health Care provides guidance on how to create and manage a medication assisted treatment program